Antimicrobial Properties
SGS bactericidal mechanisms, leech microbiome, complement-mediated killing, and the infection paradox
Research Classification
Last updated: November 1, 2026
The medicinal leech occupies a paradoxical position with respect to infection. On one hand, SGS contains components with documented antimicrobial activity, and the leech’s intestinal environment destroys or attenuates many pathogenic organisms. On the other hand, the leech harbors symbiotic bacteria — principally Aeromonas veronii biovar sobria — that may cause wound infection in vulnerable patients. Clinical practice must account for both aspects of this duality.
Historical Experimental Evidence
Early investigators observed that some microorganisms can survive for a time in the leech digestive tract, a question later studied experimentally.
| Pathogen | Detection in Leech Intestinal Blood | Outcome |
|---|---|---|
| Bact. typhi abdominalis | Present in first days; barely detectable by day 16 | Killed in intestinal canal |
| Bact. paratyphus | Undetectable at 3 months | Killed in intestinal canal |
| Bact. suiseptici | Visible at day 10; undetectable at day 38 | Killed in intestinal canal |
| Anthrax bacillus | Morphologically indistinct by day 3; absent from smears by day 17; detected by guinea pig inoculation | Attenuated but virulent residue persists |
| Plague bacillus | Blood from 4 leeches injected into healthy guinea pig at day 20; animal became ill with typical plague | Survived in intestinal canal |
| Tuberculosis bacillus | Tested | Variable survival |
| Spirochetes | Tested | Shorter survival than bacteria |
| Trypanosoma brucei & T. equiperdum | Tested | Shorter survival than bacteria |
Andreev demonstrated that SGS extracted from the cephalic region exhibits bactericidal properties against many — but not all — infectious agents. Protozoa survived for shorter periods than bacteria. A critical finding: transmission of pathogens from an infected to a healthy animal is possible only if a leech previously fed on an infected host is applied to a new animal — underscoring the absolute requirement for single-use leeches in clinical practice.
Petrov et al. (1936)
Extract from leech heads inhibited Staphylococcus growth in vitro; at higher concentrations, it killed the organisms. Chamberland-filtered extract retained weaker bactericidal activity.
Shpolyansky (1944)
In patients with parametritis, the antimicrobial effect was calculated from the difference in the number of colonies growing on agar and in blood serum collected before and after hirudotherapy. The number of staphylococcal colonies decreased 2–3 fold.
Shishkina (1953)
Confirmed that Staphylococcus aureus is killed within the leech intestinal canal within one month.
Bosz & Delezenne (in Blumenthal, 1936)
Dogs infected with lethal doses of streptococci survived when pretreated with leeches; untreated controls died.
Modern Antimicrobial Mechanisms of SGS
Four distinct antimicrobial mechanisms have been identified in SGS and the leech intestinal environment. Together they form an integrated antimicrobial system that protects both the leech (from pathogen contamination of ingested blood) and, incidentally, the host (from wound infection at the bite site).
1. Destabilase-Lysozyme (Direct Antimicrobial)
A dual-function enzyme (12.3 kDa) with muramidase activity that hydrolyses peptidoglycan in bacterial cell walls. Gram-positive bacteria are most susceptible. The same protein exhibits isopeptidase (thrombolytic) activity — cleaving ε-(γ-Glu)-Lys bonds in stabilized fibrin. Zavalova et al. (2000) demonstrated intrinsic lysozyme-like activity of destabilase, and a later study of the recombinant protein showed both isopeptidase and muramidase activities in one molecule (Zavalova et al., 2010).
Destabilase-lysozyme represents the primary direct antimicrobial effector in SGS. Three recombinant isoforms have been produced and characterized(Kurdyumov et al., 2015); a 1.1 Å crystal structure of destabilase was later reported (Marin et al., 2023).
2. Enhancement of Phagocytosis
SGS enhances the phagocytic activity of neutrophils and macrophages at the bite site and within the leech intestinal canal. Leech extracts activate phagocytosis in vitro, suggesting that SGS components serve as opsonins or direct activators of phagocytic cells. This mechanism augments the host’s innate immune response rather than replacing it.
3. Complement-Mediated Bactericidal Activity
In the leech intestinal canal, the complement cascade in ingested blood activates and forms the C5b-9 membrane attack complex, which inserts into bacterial cell membranes and causes lysis. This mechanism is effective against E. coli (sharply decreased by 42 hours) but ineffective against Aeromonas strains of serogroup O:11, whose S-layer protein (52 kDa) appears to cover the lipopolysaccharide so that complement is not activated (Merino et al., 1996).
4. Complement Modulation (Dual Role)
A complex relationship exists between SGS and complement. SGS can block complement activation via both classical and alternative pathways through the C1s complement inhibitor. This creates an evolutionary paradox: complement kills susceptible pathogens in ingested blood (beneficial), but SGS eventually attenuates complement activity (protecting the symbiotic Aeromonas population). The leech has evolved to permit initial complement-mediated pathogen clearance while preserving its digestive symbiont.
Antimicrobial Evidence: In Vitro and Microbiological Findings
Uncontrolled Russian-language report (not independently verifiable)
273 patients with acute external otitis, chronic otitis media, and tinnitus were treated with one of three modalities:
| Modality | Sessions | Outcome |
|---|---|---|
| SGS via microelectrophoresis | 1 (single session) | 25–30% less effective than full HT |
| Standard hirudotherapy | 2–9 sessions | Best microbial reduction + microcirculation |
| Conventional pharmacotherapy | Standard course | Reference comparator |
In all cases, a reduction in colony counts of Staphylococcus aureus, Escherichia coli, and Proteus spp. was observed on the skin surface of the external auditory canal, indicating an antimicrobial effect attributable to destabilase-lysozyme. The SGS microelectrophoresis result is significant: even a single session of purified SGS delivery produced measurable antimicrobial activity, confirming that the pharmacological activity of SGS is distinct from mechanical blood extraction.
The Leech Microbiome: Aeromonas Symbiosis
The identification of the leech’s intestinal symbiont has undergone significant taxonomic revision. Early studies reported a single species, Pseudomonas hirudinis (Büsing 1951), later re-identified as Aeromonas hydrophila (Whitlock, O’Hare et al. 1983). Graf (1999) re-identified the predominant culturable symbiont as Aeromonas veronii biovar sobria by biochemical tests and 16S rDNA sequencing.
Graf (1999): Taxonomic Identification of the Gut Symbiont
Analyzing intestinal canal extracts from European and Mediterranean leeches using 10 specific biochemical tests on 13 intestinal canal extracts, Graf demonstrated that the predominant culture is Aeromonas veronii biovar sobria — not A. hydrophila as previously assumed. Confirmed by genetic analysis. The presence of a pure culture in the leech intestinal canal is remarkable, since animal digestive tracts are typically colonized by complex microbial consortia.
Population Dynamics
The primary stimulus for A. veronii biovar sobria proliferation is ingested blood:
- Baseline: 2 × 104 CFU/mL
- 1 hour post-feeding: 2.5 × 105 CFU/mL (native gut flora; Wilde, cited in Graf 1999)
- Doubling time: 1.2 hours
- 12-hour plateau: 5 × 106 CFU/mL
- Total at plateau: 8 × 107 CFU/mL
The leech permits unrestricted growth for the first 12 hours until threshold density is reached, after which proliferation is balanced by bacterial removal (possibly through hemocytosis). One hypothesis holds that proteinase inhibitors (eglins, bdellins) present in the intestinal canal inhibit bacterial proliferation after the blood has resided there for 12 hours (Baskova & Isakhanyan, 2004).
Symbiont Functions
A. veronii biovar sobria serves essential digestive functions that the leech cannot perform independently:
- Haemolysis: Erythrocyte lysis for nutrient release
- Enzyme synthesis: Amylase, lipases, proteases
- Vitamin production: Essential cofactors (hypothesized; Graf et al., 2006)
- Bacteriostatic protein: Prevents blood coagulation
- Competitive exclusion: Suppresses other bacteria
The bacterium permanently inhabits the digestive tract; its role is defined by its ability to synthesize the digestive enzymes the leech itself does not produce.
Aeromonas Species in Leech Microbiome
Graf (1999) compared the leech isolates with the following reference <em>Aeromonas</em> species (data taken from the published literature); only <em>A. veronii</em> biovar <em>sobria</em> was identified in the leech crop:
Complement-Mediated Killing Mechanism
The elegant study by Indergand & Graf (2000) elucidated the complement-dependent mechanism underlying differential pathogen survival in the leech intestinal canal.
| Organism | Complement Sensitivity | 42-Hour Result | 162-Hour Result | Mechanism |
|---|---|---|---|---|
| E. coli | Sensitive | Sharply decreased | Partial recovery (complement inactivation) | C5b-9 membrane lysis |
| Aeromonas spp. | Resistant | Unrestricted growth | Plateau at 8 × 107 CFU/mL | S-layer protein (52 kDa) covers the LPS, so complement is not activated (serogroup O:11) |
| P. aeruginosa | Partially resistant | Suppressed proliferation | Persisted 162h | Partial complement resistance + competition |
| S. aureus | Partially resistant | Suppressed proliferation | Persisted 162h | Gram-positive wall + competition |
Evolutionary Interpretation
Comprehensive Flora Analysis
Eroglu et al. (2001) — 73 Isolates from 16 Specimens
Bacteria were isolated from the body surface, oral cavity (7/16 specimens), and intestinal canal (15/16 specimens). The 73 isolates comprised:
| Organism | Count | % of Total |
|---|---|---|
| A. hydrophila | 25 | 34% |
| Ochrobactrum anthropi | 23 | 32% |
| Non-fermenting GNB | 12 | 16% |
| Acinetobacter lwoffii | 3 | 4% |
| A. sobria | 2 | 3% |
| Other species | 8 | 11% |
Sources of Contamination
Indergand & Graf (2000) identified multiple potential contamination sources:
- Leech body surface: Environmental organisms from storage water
- Anterior sucker cavity: Microflora may be present (SGS itself is sterile)
- Patient skin flora: Normal commensal organisms at application site
- Prior blood meals: Critically important — during feeding, the leech may regurgitate intestinal contents into the wound. Leeches used in biofactories with multiple feedings pose highest risk
Critical Safety Implication
Clinical Infection Rates
Aeromonas species are present in freshwater environments and are pathogenic for humans and fish (Janda & Abbott, 1998). A. hydrophila, A. veronii biovar sobria, and A. caviae cause septicemia, wound infections, and diarrhea in humans.
| Study | Year | Context | Infection Data |
|---|---|---|---|
| Dabb et al. | 1992 | Reconstructive surgery | 2/4 grafts lost to wound infection |
| de Chalain | 1996 | Own case review vs literature (18 + 108 cases) | 7–20% wound infection rate |
| Kount | 1994 | Reconstructive surgery | Up to 20% Aeromonas infection |
| Mercer et al. | 1987 | Reconstructive surgery | Up to 20% infection rate |
| Tissot-Guerraz et al. | 1987 | Post-mastectomy | ML application reduced A. hydrophila content |
Risk Factors
- Immunocompromised status: Infections reported in patients with immunological complications or circulatory disorders (Dickson 1984; Abrutyn 1988; Wells 1993)
- Reconstructive surgery context: Daily application for graft salvage
- Circulatory disorders: Impaired local immune response
- Non-fasted leeches: Higher bacterial load from prior meals
In the majority of disease cases, patients' immunity had been suppressed at baseline or as a result of medical interventions, supporting classification as opportunistic infections (Khomyakova et al.).
Long-Term Clinical Experience
Uncontrolled Russian-language reports describe long-term clinical practice with the following protocol: skin prepared with non-sterile cotton swab, hands washed with ordinary tap water without soap, non-sterile dressings applied. Despite these minimal aseptic measures, wound suppuration or signs of infection were reportedly not observed. Because these accounts are not independently verifiable, they should be read with caution; nonetheless they are consistent with the general observation that in immunocompetent patients with properly fasted leeches, the infection risk is low and manageable with standard wound care.
Antibiotic Sensitivity Profile
| Antibiotic Class | Agents | Sensitivity | Notes |
|---|---|---|---|
| Fluoroquinolones | Ciprofloxacin | 100% | Broad coverage; first-line prophylaxis |
| 3rd-gen cephalosporins | Cefotaxime, ceftazidime | 100% | IV option for serious infections |
| Aminoglycosides | Gentamicin | 100% | Parenteral; monitor renal function |
| TMP/SMX | Trimethoprim/sulfamethoxazole | 100% | Oral alternative |
| 1st-gen cephalosporins | Cephalexin, cefazolin | HIGH RESISTANCE | NOT recommended for Aeromonas |
Modern Resistance Concerns
Pathogenicity: Mouse Model Data
Virulence Studies
Laboratory studies demonstrated high pathogenicity of Aeromonas strains isolated from the leech intestine:
- Intraperitoneal injection of 24-hour bacterial culture suspension at doses of 500, 100, 20, and even 4 organisms caused death at various time points with signs of sepsis.
- Addition of antibiotics to leech feed at biofactories increased mean time to death and lowered the LD50, indicating that husbandry practices modulate symbiont virulence.
These data highlight the importance of biofactory quality control: antibiotic management of leech feed can directly reduce the virulence of the bacterial population transmitted during clinical use.
Integrated Antimicrobial Model: Four Systems
The antimicrobial context of hirudotherapy involves the interplay of four distinct systems, each with specific targets and limitations:
| System | Mechanism | Target | Limitation |
|---|---|---|---|
| 1. SGS Direct | Destabilase-lysozyme cell wall hydrolysis + phagocytosis enhancement | Gram-positive bacteria (primary); broad antimicrobial at bite site | Limited against Gram-negative organisms with protective outer membranes |
| 2. Complement | C5b-9 membrane attack complex in ingested blood | Complement-sensitive organisms (E. coli, many pathogens) | Ineffective against Aeromonas (S-layer resistance) |
| 3. SGS Modulation | C1s complement inhibitor blocks classical + alternative pathways | Attenuates complement over time (protects symbiont) | Reduces complement-mediated killing of susceptible pathogens |
| 4. Competitive Exclusion | A. veronii dominance via bacteriostatic proteins + resource competition | Suppresses proliferation of non-symbiotic organisms | Does not eliminate persistent organisms (P. aeruginosa, S. aureus) |
The clinical antimicrobial action of hirudotherapy at the bite site reflects the balance between SGS antimicrobial components (destabilase-lysozyme, phagocytosis enhancement) and the potential for Aeromonas transmission from the intestinal canal. Proper leech preparation, patient selection, and prophylactic antibiotic use shift this balance toward net antimicrobial benefit.
Infection Prevention Strategies
1. Leech Husbandry & Quality Control
- Maintain leeches in clean water free of pathogens with mandatory microbiological testing
- Use only blood from healthy, tested animals for biofactory feeding
- Use only fasted leeches (minimum 6 months without feeding)
- Test random samples for intestinal blood presence before clinical use
2. Pre-Treatment Preparation
Mackay et al. (1999) incubated leeches for 12 hours in antibiotic solutions and found that this failed to eradicate pathogenic bacteria from the leech gut; they endorsed broad-spectrum prophylactic antibiotics for patients receiving leech therapy instead.
3. Prophylactic Antibiotics
For patients at elevated risk (immunocompromised, post-surgical, reconstructive), prophylactic antibiotics active against Aeromonas are recommended. First-line: ciprofloxacin (oral) or cefotaxime/ceftazidime (IV). First-generation cephalosporins are not effective.
4. Patient Selection & Monitoring
- Screen for immunocompromised status (highest risk group)
- Monitor wound for signs of infection after treatment (onset reported 1-11 days after leeching in published series, occasionally weeks later)
- Obtain wound culture for any suspected infection with specific Aeromonas request
- Initiate empiric antibiotics pending sensitivity results
Evidence Summary
GRADE Evidence Level: Low
Observational studies or RCTs with serious limitations
The antimicrobial properties of SGS are documented primarily through in vitro studies, animal experiments, and microbiological characterization. Clinical evidence is limited to uncontrolled, non-indexed Russian-language reports that are not independently verifiable. No randomized controlled trials have specifically evaluated SGS antimicrobial efficacy.
| Study | Design | Population (n=) | Intervention | Key Outcome | Result |
|---|---|---|---|---|---|
| Andreev PN 1923 | In vivo / animal model | Leeches fed on infected guinea pigs, rats, chickens (n=NR) | Pathogen survival assay in leech intestinal canal | Pathogen viability over time | Andreev (1923) found highly variable pathogen survival in the leech gut: typhoid bacillus was barely detectable by day 16, and paratyphoid bacillus could no longer be detected in the blood ingested by the leech three months later; anthrax bacilli became undetectable by direct smear by day 17 but were still confirmed viable by guinea pig inoculation; plague bacillus remained viable through day 20 and was transmitted via injected leech blood to a healthy guinea pig, which became ill and, when euthanized after 16 days, showed the typical picture of plague at autopsy. Pioneering pathogen survival study |
| Petrov IR et al. 1936 | In vitro | Staphylococcus cultures (n=NR) | Extract from leech heads applied to bacterial cultures | Bactericidal activity | Staphylococcus growth inhibited at low concentrations; killed at higher concentrations. Chamberland-filtered extract retained weaker activity. Early in vitro antimicrobial evidence |
| Shpolyansky GM 1944 | Prospective observational | Parametritis patients (n=NR) | Hirudotherapy | Staphylococcal colony counts on agar | Colony numbers decreased 2–3 fold after hirudotherapy. Clinical antimicrobial observation |
| Graf J 1999 | Biochemical / taxonomic characterization | European and Mediterranean medicinal leeches (n=13) | 10 specific biochemical tests on intestinal canal extracts | Symbiont species identification | Predominant culture is A. veronii biovar sobria (not A. hydrophila as assumed). Confirmed by genetic analysis. Pure culture in intestinal canal is remarkable. J Clin Microbiol |
| Indergand S & Graf J 2000 | In vitro / controlled | E. coli, P. aeruginosa, S. aureus in leech intestinal environment (n=NR) | Pathogen introduction into leech intestinal canal with complement analysis | Pathogen survival and complement-mediated killing | E. coli sharply decreased by 42h (complement C5b-9 lysis); Aeromonas resistant due to S-layer protein. P. aeruginosa and S. aureus persisted 162h but proliferation suppressed. Complement-mediated mechanism elucidated |
| Eroglu C et al. 2001 | Microbiological survey | Medicinal leech specimens (surface, oral cavity, intestinal canal) (n=16) | Bacterial isolation and identification from 73 isolates | Flora characterization and antibiotic sensitivity | A. hydrophila (n=25), O. anthropi (n=23), NFGNB (n=12), A. lwoffii (n=3), A. sobria (n=2). 100% sensitivity to ciprofloxacin, cefotaxime, ceftazidime, gentamicin, TMP/SMX. Full flora + sensitivity data |
| de Chalain TM 1996 | Case review with literature comparison | Pedicled and free flaps treated with leeches (n=126) | Hirudotherapy for venous congestion | Flap salvage and wound infection rate | 18 own cases contrasted with 108 published cases from other centres: salvage in 70–80%, infection rate 7–20% in most series; with clinically significant infection, salvage fell to 30% or less (19 infection cases analysed). J Reconstr Microsurg 1996;12(3):165–72 (PMID 8726336) |
| Zavalova LL et al. 2000 | Biochemical characterization | Hirudo medicinalis SGS (n=NR) | Recombinant destabilase expression and functional assay | Dual isopeptidase + lysozyme activity | Destabilase exhibits both isopeptidase (thrombolytic) and muramidase (antibacterial) activities in a single 12.3 kDa protein. Primary direct antimicrobial effector in SGS. Biochemistry (Moscow) |
| Seleznev KG et al. 1992 | Clinical comparison | Tinnitus from inner-ear disease, acute external otitis, chronic otitis media (n=NR) | Medicinal leeches vs diluted SGS delivered by microelectrophoresis to the mastoid region | Clinical effect; microbial counts on the auditory canal | SGS by microelectrophoresis was 25–30% less effective than leech application; treatment reduced the number of microorganisms on the external auditory canal. ORL J Otorhinolaryngol Relat Spec 1992;54(1):1–4 (PMID 1584585) |
Evidence Gaps & Research Priorities
What We Know
- Destabilase-lysozyme is the primary direct antimicrobial in SGS
- Complement-mediated killing operates in the intestinal canal
- The predominant symbiont is A. veronii biovar sobria
- Infection rates: 7–20% in reconstructive surgery
- Fluoroquinolones, 3rd-gen cephalosporins: 100% sensitivity in one series (Eroglu 2001, 16 leeches); resistant strains reported since
- 1st-gen cephalosporins: NOT effective
What Remains Unknown
- Quantitative MIC values for destabilase-lysozyme against clinical isolates
- Role of antimicrobial peptides beyond destabilase in SGS
- Optimal prophylaxis duration (pre- vs post-treatment)
- Impact of ESBL and carbapenem-resistant Aeromonas on clinical protocols
- Whether SGS antimicrobial activity persists beyond the acute feeding period
- Comparative infection rates between medicinal leech species
ASH supports the development of standardized antimicrobial susceptibility testing protocols for leech-associated organisms and prospective surveillance studies to monitor resistance trends in clinical Aeromonas isolates.
Key Takeaways
- 1. SGS exerts direct antimicrobial activity through destabilase-lysozyme (cell wall hydrolysis), enhancement of phagocytosis, and complement-mediated bactericidal reactions.
- 2. The predominant leech intestinal symbiont is A. veronii biovar sobria (not A. hydrophila), confirmed by biochemical and genetic analysis (Graf 1999). It proliferates in ingested blood in which the complement membrane-attack complex remains active (Indergand and Graf 2000); whether an S-layer protects it has not been determined.
- 3. Infection rates in published leech-therapy series range from 7–20% (Aeromonas is the main pathogen; 14.2% in one 35-patient series), primarily in reconstructive surgery and immunocompromised patients.
- 4. Effective antibiotics: ciprofloxacin, 3rd-gen cephalosporins, aminoglycosides (100% sensitivity in the Eroglu 2001 isolates; resistant strains have since been reported). First-generation cephalosporins are ineffective.
- 5. Infection risk is minimized by fasted leeches (≥6 months), strict husbandry, prophylactic antibiotics in high-risk patients, and wound culture for any suspected infection.
- 6. The antimicrobial balance reflects an evolutionary interplay between anti-pathogen mechanisms and symbiont-protective adaptations; clinical practice must account for both sides of this duality.
Methodology & deeper dives: Aeromonas risk & prophylaxis · hirunipins (AMP) · /how-evidence-graded.